sunitinib eg 25 mg gél.
eg sa-nv - sunitinib 25 mg - gélule - 25 mg - sunitinib 25 mg - sunitinib
sunitinib eg 37.5 mg gél.
eg sa-nv - sunitinib 37,5 mg - gélule - 37,5 mg - sunitinib 37.5 mg - sunitinib
sunitinib eg 50 mg gél.
eg sa-nv - sunitinib 50 mg - gélule - 50 mg - sunitinib 50 mg - sunitinib
sunitinib mylan 37,5 mg, gélule
mylan sas - sunitinib - gélule - 37,5 mg - composition pour une gélule > sunitinib : 37,5 mg - agent antinéoplasique, inhibiteur de protéine kinase
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agents antinéoplasiques - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
sunitinib teva 12.5 mg gél.
teva b.v. - sunitinib 12,5 mg - gélule - sunitinib
sunitinib teva 25 mg gél.
teva b.v. - sunitinib 25 mg - gélule - sunitinib
sunitinib teva 37.5 mg gél.
teva b.v. - sunitinib 37,5 mg - gélule - sunitinib
sunitinib teva 50 mg gél.
teva b.v. - sunitinib 50 mg - gélule - sunitinib
sunitinib krka 12.5 mg gél.
krka d.d. novo mesto d.d. - malate de sunitinib 16,71 mg - eq. sunitinib 12,5 mg - gélule - 12,5 mg - malate de sunitinib 16.71 mg - sunitinib